Back to All Combinations

KRAS G12C + STK11

Intermediate Prognosis
0.50% Prevalence B General
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
KRAS G12C STK11
Recommended Treatments
Sotorasib + Panitumumab
Adagrasib + Cetuximab
Treatments to Avoid
Immunotherapy alone
Key Statistics
0.50%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Very rare in CRC (<1%). STK11 co-mutation impact less studied in CRC than NSCLC. KRAS G12C inhibitors remain primary treatment.
Information

Category: General

Evidence Level: B

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.